Stan Watowich | Aging Biology, Drug Discovery, and Building Around High-Conviction Science
Stan Watowich joins Executive Insights for Life Sciences Innovators to discuss aging biology, drug discovery, biotech company building, and the scientific and commercial opportunities emerging around chronic disease research.
Prefer audio only? Listen to this episode on Spotify.
Episode Overview
In this episode, Stan Watowich discusses Ridgeline Therapeutics’ approach to developing small molecule therapies targeting NNMT, a regulator of cellular energetics linked to aging and chronic disease. The conversation explores drug discovery, translational science, company-building, and the challenges of advancing high-conviction science in today’s biotech environment.
Key Themes
- Aging biology and chronic disease research
- Small molecule drug discovery targeting NNMT
- Translating academic science into biotech companies
- Structural biology and therapeutic innovation
- Building biotech companies around high-conviction science
- Funding and commercialization challenges in emerging biotech
Why This Matters for Life Sciences Leaders
As biotechnology companies pursue new approaches to aging biology and chronic disease, leaders must balance scientific ambition with disciplined execution and capital strategy. The conversation highlights how emerging therapeutic platforms move from academic discovery into commercial development, and why conviction, translational rigor, and long-term thinking remain critical in building durable biotech companies.
Guest Link
More from Executive Insights
Explore more conversations with life sciences founders, CEOs, investors, and operators on the Executive Insights for Life Sciences Innovators podcast.
